Antilymphocyte Serum
Immunosuppression
Anemia, Aplastic
Transplantation Immunology
Chromium Isotopes
Iodine Isotopes
Fetal Hemoglobin
Pancytopenia
Bone Marrow Diseases
Erythropoiesis
Anemia, Macrocytic
Tissue and Organ Procurement
Tissue Donors
Organ Transplantation
Automobile Driver Examination
Biometric Identification
Ethics, Medical
Immunological control of a murine gammaherpesvirus independent of CD8+ T cells. (1/1079)
Adult thymectomized C57 BL/6J mice were depleted of T cell subsets by MAb treatment either prior to, or after, respiratory challenge with murine gammaherpesvirus-68. Protection against acute infection was maintained when either the CD4+ or the CD8+ T cell population was greatly diminished, whereas the concurrent removal of both T cell subsets proved invariably fatal. The same depletions had little effect on mice with established infection. The results indicate firstly that both CD4+ and CD8+ T cells play a significant part in dealing with the acute infection, and secondly that virus-specific antibody contributes to controlling persistent infection with this gammaherpesvirus. (+info)Long-term results of pancreas transplantation under tacrolius immunosuppression. (2/1079)
BACKGROUND: The long-term safety and efficacy of tacrolimus in pancreas transplantation has not yet been demonstrated. The observation of prolonged pancreatic graft function under tacrolimus would indicate that any potential islet toxicity is short-lived and clinically insignificant. We report herein the results of pancreas transplantation in patients receiving primary tacrolimus immunosuppression for a minimum of 2 years. METHODS: From July 4, 1994 until April 18, 1996, 60 patients received either simultaneous pancreas-kidney transplant (n=55), pancreas transplant only (n=4), or pancreas after kidney transplantation (n=1). Baseline immunosuppression consisted of tacrolimus and steroids without antilymphocyte induction. Azathioprine was used as a third agent in 51 patients and mycophenolate mofetil in 9. Rejection episodes within the first 6 months occurred in 48 (80%) patients and were treated with high-dose corticosteroids. Antilymphocyte antibody was required in eight (13%) patients with steroid-resistant rejection. RESULTS: With a mean follow-up of 35.1+/-5.9 months (range: 24.3-45.7 months), 6-month and 1-, 2-, and 33-year graft survival is 88%, 82%, 80%, and 80% (pancreas) and 98%, 96%, 93%, and 91% (kidney), respectively. Six-month and 1-, 2-, and 3-year patient survival is 100%, 98%, 98%, and 96.5%. Mean fasting glucose is 91.6+/-13.8 mg/dl, and mean glycosylated hemoglobin is 5.1+/-0.7% (normal range: 4.3-6.1%). Mean tacrolimus dose is 6.5+/-2.6 mg/day and mean prednisone dose 2.0+/-2.9 mg/day at follow-up. Complete steroid withdrawal was possible in 31 (65%) of the 48 patients with functioning pancreases. CONCLUSIONS: These data show for the first time that tacrolimus is a safe and effective long-term primary agent in pancreas transplantation and provides excellent long-term islet function without evidence of toxicity while permitting steroid withdrawal in the majority of patients. (+info)Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. (3/1079)
We report the results of the first prospective randomized multicenter study of immunosuppressive treatment in patients with previously untreated nonsevere aplastic anemia (AA) as defined by a neutrophil count of at least 0.5 x 10(9)/L and transfusion dependence. Patients were randomized to receive cyclosporin (CSA) alone or the combination of horse antithymocyte globulin ([ATG] Lymphoglobuline; Merieux, Lyon, France) and CSA. The endpoint of the study was the hematologic response at 6 months. One hundred fifteen patients were randomized and assessable with a median follow-up period of 36 months; 61 received CSA and 54 ATG and CSA. In the CSA group, the percentage of complete and partial responders was 23% and 23%, respectively, for an overall response rate of 46%. A significantly higher overall response rate of 74% was found in the ATG and CSA group, with 57% complete and 17% partial responders (P =. 02). Compared with CSA alone, the combination of ATG and CSA resulted in a significantly higher median hemoglobin level and platelet count at 6 months. Fewer patients required a second course of treatment before 6 months due to a nonresponse. In the CSA group, 15 of 61 (25%) patients required a course of ATG before 6 months because of disease progression, compared with only 3 of 54 (6%) in the ATG and CSA group. The survival probabilities for the two groups were comparable, 93% (CSA group) and 91% (ATG and CSA group), but at 180 days, the prevalence of patients surviving free of transfusions, which excluded patients requiring second treatment because of nonresponse, death, disease progression, or relapse, was 67% in the CSA group and 90% in the ATG and CSA group (P =.001). We conclude that the combination of ATG and CSA is superior to CSA alone in terms of the hematologic response, the quality of response, and early mortality, and a second course of immunosuppression is less frequently required. (+info)Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. (4/1079)
To determine whether the antigen-driven T-cell response is involved in the pathogenesis of aplastic anemia (AA), we examined the complementarity-determining region 3 (CDR3) size distribution of T-cell receptor (TCR) beta-chain (BV) subfamilies in the bone marrow (BM) of untreated AA patients. AA patients who did not respond to immunosuppressive therapy and those who obtained unmaintained remission early after cyclosporine (CyA) or antithymocyte globulin (ATG) therapy exhibited essentially a normal CDR3 size pattern. In contrast, five patients who needed continuous administration of CyA to maintain remission exhibited a skewed CDR3 size pattern in a number (>40%) of BV subfamilies suggestive of clonal predominance. The skewing of CDR3 size distribution became less pronounced in one of the CyA-dependent patients when the patient achieved unmaintained remission after a 4-year therapy with CyA, whereas it persisted longer than 7 years in the other patient requiring maintenance therapy. Sequencing of BV15 cDNA for which the CDR3 size pattern exhibited apparent clonal predominance in all CyA-dependent patients showed high homology of the amino acid sequence of the CDR3 between two different patients. These findings indicate that antigen-driven expansion of T cells is involved in the pathogenesis of AA characterized by CyA-dependent recovery of hematopoiesis. (+info)Late graft failure 8 years after first bone marrow transplantation for severe acquired aplastic anemia. (5/1079)
A 14-year-old patient with acquired very severe aplastic anemia (VSAA) underwent bone marrow transplantation (BMT) from his HLA-identical brother. Preparative therapy was cyclophosphamide (CY) 200 mg/kg over 4 days. GVHD prophylaxis was with cyclosporin A (CsA) for a year. After an 8 year follow-up during which the patient was well with normal blood counts, graft failure occurred. At this time marrow chimerism studies demonstrated that 85% of hemopoiesis was of recipient origin. The patient was re-engrafted from the same donor after conditioning with CY 200 mg/kg over 4 days plus rabbit antithymocyte globulin (ATG) 3.5 mg/kg/day for 3 days. After 140 days follow-up he has a normal blood count. The possible causes of the graft failure are discussed. This case demonstrates that, although rarely, very late graft failure may occur after BMT for AA and highlights the need for long-term monitoring even in apparently successfully transplanted patients. (+info)Monitoring anti-thymocyte globulin (ATG) in bone marrow recipients. (6/1079)
The present study was undertaken to acquire a rationale for clinical dose adjustment of anti-thymocyte globulin (ATG) to improve cost effectiveness and safety of graft-versus-host disease prophylaxis. The concentration of rabbit ATG in the serum of 12 patients was measured by ELISA and by the inhibitory effect on phytohaemagglutinin-induced blastogenesis. At 10 mg/ml ATG, 3H-thymidine incorporation was effectively blocked. Serial two-fold dilution of ATG showed that this effect decreased in a concentration-dependent manner and was lost at 10 ng/ml ATG. One hundred microlitres serum taken at day -1 to +22 post transplant effected significant inhibition of the phytohaemagglutinin-response with 49+/-12% c.p.m. (x +/- s.d.) on day +1 post transplant compared to 93+/-13% c.p.m. on day -1 (P<0.001, unpaired one-sided t-test). The rabbit-IgG was maximal at a concentration of 907+/-187 microl/ml at day 0. Subsequently, it decreased with time. While rabbit-IgG was detectable for a long period (e.g. 160 microg/ml at day +22 in patient MD), the effect on the phytohaemagglutinin-response of normal mononuclear cells lasted up to 4 days post transplant. We conclude that 90 mg/kg body weight ATG-Fresenius given prior to marrow transplant leads to sustained T cell immunosuppression post transplant. (+info)Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow. (7/1079)
A five-agent GVHD prophylaxis programme consisting of cyclosporin A, methotrexate, anti-thymocyte-globulin, pentaglobin and metronidazol was given to 48 recipients of unrelated donor marrow with chronic myelogenous leukemia, acute leukemia, myelodysplastic syndromes, and familiar lymphocytic hemophagocytosis of an average age of 33.5 (0.6-56) years. GVHD grades II-IV occurred in 18 patients (39%) and grades III-IV in five patients (11%). Chronic GVHD developed in nine patients (23%), three limited and six extensive. Fifteen patients died. Clinical relapse was detected in eight patients. Four patients died as a consequence of the underlying disease and subsequent treatment, 11 patients died of transplant-related causes. After a median follow-up of 19 months, the overall and disease-free survival are 67% and 62%, respectively. Survival by age is as follows: 0-19 years: 12/13 patients; 20-39 years: 14/25 patients; 40-59 years: 7/10 patients. The five-agent GVHD prophylaxis regimen is effective. Matched-unrelated donor transplants can be carried out safely in patients younger than 50 years of age. The results in patients younger than 20 years of age should encourage matched-unrelated donor transplants at earlier stages of the disease. (+info)L-Arginine supplementation increases mesangial cell injury and subsequent tissue fibrosis in experimental glomerulonephritis. (8/1079)
BACKGROUND: Mesangial cell lysis in the antithymocyte serum (ATS)-induced model of glomerulonephritis is dependent on the generation of cytotoxic nitric oxide (NO) through transient induction of NO synthase (iNOS). We hypothesized that increased availability of L-arginine (L-Arg) during mesangial cell lysis might provide iNOS with increased substrate leading to increased lysis, and that this increased lysis would be reflected in more severe fibrotic disease at day 6. METHODS: To ensure whole body equilibration with high L-Arg at the time of injury, rats were pretreated with 1% L-Arg in drinking water for one week prior to the administration of ATS. Animals were sacrificed six hours after ATS injection when previous experiments had indicated iNOS induction had occurred and at six days. At six hours, plasma was obtained for L-Arg levels and nitrite/nitrate (NOx) content. Renal tissues were taken for histological evaluation of glomerular cell counts, macrophage infiltration (ED-1), and iNOS expression. Glomeruli were isolated for detection of iNOS mRNA and placed in culture to study the dependence of NO production on L-Arg concentration. In rats sacrificed at six days, L-Arg supplementation was stopped 16 hours after ATS injection. Fibrotic disease was evaluated by urinary protein excretion, histological assessment of glomerular cell number, matrix accumulation, and production of transforming growth factor-beta1 and matrix components fibronectin and plasminogen activator inhibitor type-1 (PAI-1) by isolated glomeruli in culture. RESULTS: At six hours, the glomerular cell number was significantly reduced by ATS injection (P < 0.01) and further significantly (P < 0. 05) reduced by L-Arg feeding [normal control (NC) = 64.2 +/- 1, ATS = 53.4 +/- 0.7, ATS + L-Arg = 50.8 +/- 0.7]. Disease increased macrophage infiltration and iNOS protein and iNOS mRNA levels markedly (P < 0.01), whereas L-Arg feeding did not further increase these variables. Plasma L-Arg levels (nmol/ml) were reduced by disease (NC = 121 +/- 9, ATS = 84 +/- 13, P < 0.01) and elevated by L-Arg feeding (ATS + L-Arg = 166 +/- 12, P < 0.01). Plasma NOx was significantly increased by ATS and further increased by ATS + L-Arg (P < 0.05). Production of NOx by cultured glomeruli showed striking L-Arg concentration dependence in six hours but not in normal glomeruli. In the group sacrificed at day 6, day 2 proteinuria was higher in the ATS + L-Arg group compared with the ATS alone group (P < 0.05). Measures of fibrotic disease at day 6 all showed large increases over control with ATS alone (P < 0.01), and further small, but significant increases when L-Arg was combined with ATS (P < 0.05). CONCLUSIONS: The results indicate that if given during disease induction, L-Arg supplementation can enhance iNOS-dependent tissue injury by providing increased substrate. Although the increase in injury with L-Arg supplementation was small, it led to increased fibrosis at day 6. These data predict that in diseases with repeated iNOS-dependent tissue injury, L-Arg supplementation may produce cumulative increases in tissue fibrosis. (+info)Antilymphocyte serum (ALS) is a type of immune serum that contains antibodies against human lymphocytes. It is produced by immunizing animals, such as horses or rabbits, with human lymphocytes to stimulate an immune response and the production of anti-lymphocyte antibodies. The resulting serum is then collected and can be used as a therapeutic agent to suppress the activity of the immune system in certain medical conditions.
ALS is primarily used in the treatment of transplant rejection, particularly in organ transplantation, where it helps to prevent the recipient's immune system from attacking and rejecting the transplanted organ. It can also be used in the management of autoimmune diseases, such as rheumatoid arthritis and lupus, to suppress the overactive immune response that contributes to these conditions.
It is important to note that the use of ALS carries a risk of side effects, including allergic reactions, fever, and decreased white blood cell counts. Close monitoring and appropriate management of these potential adverse events are essential during treatment with ALS.
Thymectomy is a surgical procedure that involves the removal of the thymus gland. The thymus gland is a part of the immune system located in the upper chest, behind the sternum (breastbone), and above the heart. It is responsible for producing white blood cells called T-lymphocytes, which help fight infections.
Thymectomy is often performed as a treatment option for patients with certain medical conditions, such as:
* Myasthenia gravis: an autoimmune disorder that causes muscle weakness and fatigue. In some cases, the thymus gland may contain abnormal cells that contribute to the development of myasthenia gravis. Removing the thymus gland can help improve symptoms in some patients with this condition.
* Thymomas: tumors that develop in the thymus gland. While most thymomas are benign (non-cancerous), some can be malignant (cancerous) and may require surgical removal.
* Myasthenic syndrome: a group of disorders characterized by muscle weakness and fatigue, similar to myasthenia gravis. In some cases, the thymus gland may be abnormal and contribute to the development of these conditions. Removing the thymus gland can help improve symptoms in some patients.
Thymectomy can be performed using various surgical approaches, including open surgery (through a large incision in the chest), video-assisted thoracoscopic surgery (VATS, using small incisions and a camera to guide the procedure), or robotic-assisted surgery (using a robot to perform the procedure through small incisions). The choice of surgical approach depends on several factors, including the size and location of the thymus gland, the patient's overall health, and the surgeon's expertise.
Immunosuppression is a state in which the immune system's ability to mount an immune response is reduced, compromised or inhibited. This can be caused by certain medications (such as those used to prevent rejection of transplanted organs), diseases (like HIV/AIDS), or genetic disorders. As a result, the body becomes more susceptible to infections and cancer development. It's important to note that immunosuppression should not be confused with immunity, which refers to the body's ability to resist and fight off infections and diseases.
The spleen is an organ in the upper left side of the abdomen, next to the stomach and behind the ribs. It plays multiple supporting roles in the body:
1. It fights infection by acting as a filter for the blood. Old red blood cells are recycled in the spleen, and platelets and white blood cells are stored there.
2. The spleen also helps to control the amount of blood in the body by removing excess red blood cells and storing platelets.
3. It has an important role in immune function, producing antibodies and removing microorganisms and damaged red blood cells from the bloodstream.
The spleen can be removed without causing any significant problems, as other organs take over its functions. This is known as a splenectomy and may be necessary if the spleen is damaged or diseased.
Aplastic anemia is a medical condition characterized by pancytopenia (a decrease in all three types of blood cells: red blood cells, white blood cells, and platelets) due to the failure of bone marrow to produce new cells. It is called "aplastic" because the bone marrow becomes hypocellular or "aplastic," meaning it contains few or no blood-forming stem cells.
The condition can be acquired or inherited, with acquired aplastic anemia being more common. Acquired aplastic anemia can result from exposure to toxic chemicals, radiation, drugs, viral infections, or autoimmune disorders. Inherited forms of the disease include Fanconi anemia and dyskeratosis congenita.
Symptoms of aplastic anemia may include fatigue, weakness, shortness of breath, pale skin, easy bruising or bleeding, frequent infections, and fever. Treatment options for aplastic anemia depend on the severity of the condition and its underlying cause. They may include blood transfusions, immunosuppressive therapy, and stem cell transplantation.
Skin manifestations refer to visible changes on the skin that can indicate an underlying medical condition or disease process. These changes can include rashes, lesions, discoloration, eruptions, blisters, hives, and other abnormalities. The appearance, distribution, and pattern of these manifestations can provide important clues for healthcare professionals to diagnose and manage the underlying condition.
Skin manifestations can be caused by a wide range of factors, including infections, inflammatory conditions, allergic reactions, genetic disorders, autoimmune diseases, and cancer. In some cases, skin manifestations may be the primary symptom of a medical condition, while in other cases, they may be a secondary effect of medication or treatment.
It is important to note that while skin manifestations can provide valuable diagnostic information, they should always be evaluated in the context of the patient's overall medical history and presentation. A thorough physical examination and appropriate diagnostic tests are often necessary to confirm a diagnosis and develop an effective treatment plan.
Transplantation Immunology is a branch of medicine that deals with the immune responses occurring between a transplanted organ or tissue and the recipient's body. It involves understanding and managing the immune system's reaction to foreign tissue, which can lead to rejection of the transplanted organ. This field also studies the use of immunosuppressive drugs to prevent rejection and the potential risks and side effects associated with their use. The main goal of transplantation immunology is to find ways to promote the acceptance of transplanted tissue while minimizing the risk of infection and other complications.
Chromium isotopes are different forms of the chemical element Chromium (Cr), which have different numbers of neutrons in their atomic nuclei. This results in each isotope having a different atomic mass, although they all have the same number of protons (24) and therefore share the same chemical properties.
The most common and stable chromium isotopes are Chromium-52 (Cr-52), Chromium-53 (Cr-53), Chromium-54 (Cr-54), and Chromium-56 (Cr-56). The other less abundant isotopes of Chromium, such as Chromium-50 (Cr-50) and Chromium-51 (Cr-51), are radioactive and undergo decay to become stable isotopes.
Chromium is an essential trace element for human health, playing a role in the metabolism of carbohydrates, lipids, and proteins. It is also used in various industrial applications, such as in the production of stainless steel and other alloys.
Kidney transplantation is a surgical procedure where a healthy kidney from a deceased or living donor is implanted into a patient with end-stage renal disease (ESRD) or permanent kidney failure. The new kidney takes over the functions of filtering waste and excess fluids from the blood, producing urine, and maintaining the body's electrolyte balance.
The transplanted kidney is typically placed in the lower abdomen, with its blood vessels connected to the recipient's iliac artery and vein. The ureter of the new kidney is then attached to the recipient's bladder to ensure proper urine flow. Following the surgery, the patient will require lifelong immunosuppressive therapy to prevent rejection of the transplanted organ by their immune system.
Iodine isotopes are different forms of the chemical element iodine, which have different numbers of neutrons in their nuclei. Iodine has a total of 53 protons in its nucleus, and its stable isotope, iodine-127, has 74 neutrons, giving it a mass number of 127. However, there are also radioactive isotopes of iodine, which have different numbers of neutrons and are therefore unstable.
Radioactive isotopes of iodine emit radiation as they decay towards a stable state. For example, iodine-131 is a commonly used isotope in medical imaging and therapy, with a half-life of about 8 days. It decays by emitting beta particles and gamma rays, making it useful for treating thyroid cancer and other conditions that involve overactive thyroid glands.
Other radioactive iodine isotopes include iodine-123, which has a half-life of about 13 hours and is used in medical imaging, and iodine-125, which has a half-life of about 60 days and is used in brachytherapy (a type of radiation therapy that involves placing radioactive sources directly into or near tumors).
It's important to note that exposure to radioactive iodine isotopes can be harmful, especially if it occurs through inhalation or ingestion. This is because the iodine can accumulate in the thyroid gland and cause damage over time. Therefore, appropriate safety measures must be taken when handling or working with radioactive iodine isotopes.
Fetal hemoglobin (HbF) is a type of hemoglobin that is produced in the fetus and newborn babies. It is composed of two alpha-like globin chains and two gamma-globin chains, designated as α2γ2. HbF is the primary form of hemoglobin during fetal development, replacing the embryonic hemoglobin (HbG) around the eighth week of gestation.
The unique property of HbF is its higher affinity for oxygen compared to adult hemoglobin (HbA), which helps ensure adequate oxygen supply from the mother to the developing fetus. After birth, as the newborn starts breathing on its own and begins to receive oxygen directly, the production of HbF gradually decreases and is usually replaced by HbA within the first year of life.
In some genetic disorders like sickle cell disease and beta-thalassemia, persistence of HbF into adulthood can be beneficial as it reduces the severity of symptoms due to its higher oxygen-carrying capacity and less polymerization tendency compared to HbS (in sickle cell disease) or unpaired alpha chains (in beta-thalassemia). Treatments like hydroxyurea are used to induce HbF production in these patients as a therapeutic approach.
Pancytopenia is a medical condition characterized by a reduction in the number of all three types of blood cells in the peripheral blood: red blood cells (anemia), white blood cells (leukopenia), and platelets (thrombocytopenia). This condition can be caused by various underlying diseases, including bone marrow disorders, viral infections, exposure to toxic substances or radiation, vitamin deficiencies, and certain medications. Symptoms of pancytopenia may include fatigue, weakness, increased susceptibility to infections, and easy bruising or bleeding.
Bone marrow diseases, also known as hematologic disorders, are conditions that affect the production and function of blood cells in the bone marrow. The bone marrow is the spongy tissue inside bones where all blood cells are produced. There are various types of bone marrow diseases, including:
1. Leukemia: A cancer of the blood-forming tissues, including the bone marrow. Leukemia causes the body to produce large numbers of abnormal white blood cells, which can crowd out healthy blood cells and impair their function.
2. Lymphoma: A cancer that starts in the lymphatic system, which is part of the immune system. Lymphoma can affect the bone marrow and cause an overproduction of abnormal white blood cells.
3. Multiple myeloma: A cancer of the plasma cells, a type of white blood cell found in the bone marrow. Multiple myeloma causes an overproduction of abnormal plasma cells, which can lead to bone pain, fractures, and other complications.
4. Aplastic anemia: A condition in which the bone marrow does not produce enough new blood cells. This can lead to symptoms such as fatigue, weakness, and an increased risk of infection.
5. Myelodysplastic syndromes (MDS): A group of disorders in which the bone marrow does not produce enough healthy blood cells. MDS can lead to anemia, infections, and bleeding.
6. Myeloproliferative neoplasms (MPNs): A group of disorders in which the bone marrow produces too many abnormal white or red blood cells, or platelets. MPNs can lead to symptoms such as fatigue, itching, and an increased risk of blood clots.
Treatment for bone marrow diseases depends on the specific condition and its severity. Treatment options may include chemotherapy, radiation therapy, stem cell transplantation, or targeted therapies that target specific genetic mutations.
Anemia is a medical condition characterized by a lower than normal number of red blood cells or lower than normal levels of hemoglobin in the blood. Hemoglobin is an important protein in red blood cells that carries oxygen from the lungs to the rest of the body. Anemia can cause fatigue, weakness, shortness of breath, and a pale complexion because the body's tissues are not getting enough oxygen.
Anemia can be caused by various factors, including nutritional deficiencies (such as iron, vitamin B12, or folate deficiency), blood loss, chronic diseases (such as kidney disease or rheumatoid arthritis), inherited genetic disorders (such as sickle cell anemia or thalassemia), and certain medications.
There are different types of anemia, classified based on the underlying cause, size and shape of red blood cells, and the level of hemoglobin in the blood. Treatment for anemia depends on the underlying cause and may include dietary changes, supplements, medication, or blood transfusions.
Erythropoiesis is the process of forming and developing red blood cells (erythrocytes) in the body. It occurs in the bone marrow and is regulated by the hormone erythropoietin (EPO), which is produced by the kidneys. Erythropoiesis involves the differentiation and maturation of immature red blood cell precursors called erythroblasts into mature red blood cells, which are responsible for carrying oxygen to the body's tissues. Disorders that affect erythropoiesis can lead to anemia or other blood-related conditions.
Macrocytic anemia is a type of anemia in which the red blood cells are larger than normal in size (macrocytic). This condition can be caused by various factors such as deficiency of vitamin B12 or folate, alcohol abuse, certain medications, bone marrow disorders, and some inherited genetic conditions.
The large red blood cells may not function properly, leading to symptoms such as fatigue, weakness, shortness of breath, pale skin, and a rapid heartbeat. Macrocytic anemia can be diagnosed through a complete blood count (CBC) test, which measures the size and number of red blood cells in the blood.
Treatment for macrocytic anemia depends on the underlying cause. In cases of vitamin B12 or folate deficiency, supplements or dietary changes may be recommended. If the anemia is caused by medication, a different medication may be prescribed. In severe cases, blood transfusions or injections of vitamin B12 may be necessary.
Tissue and organ procurement is the process of obtaining viable tissues and organs from deceased or living donors for the purpose of transplantation, research, or education. This procedure is performed by trained medical professionals in a sterile environment, adhering to strict medical standards and ethical guidelines. The tissues and organs that can be procured include hearts, lungs, livers, kidneys, pancreases, intestines, corneas, skin, bones, tendons, and heart valves. The process involves a thorough medical evaluation of the donor, as well as consent from the donor or their next of kin. After procurement, the tissues and organs are preserved and transported to recipients in need.
A tissue donor is an individual who has agreed to allow organs and tissues to be removed from their body after death for the purpose of transplantation to restore the health or save the life of another person. The tissues that can be donated include corneas, heart valves, skin, bone, tendons, ligaments, veins, and cartilage. These tissues can enhance the quality of life for many recipients and are often used in reconstructive surgeries. It is important to note that tissue donation does not interfere with an open casket funeral or other cultural or religious practices related to death and grieving.
Organ transplantation is a surgical procedure where an organ or tissue from one person (donor) is removed and placed into another person (recipient) whose organ or tissue is not functioning properly or has been damaged beyond repair. The goal of this complex procedure is to replace the non-functioning organ with a healthy one, thereby improving the recipient's quality of life and overall survival.
Organs that can be transplanted include the heart, lungs, liver, kidneys, pancreas, and intestines. Tissues such as corneas, skin, heart valves, and bones can also be transplanted. The donor may be deceased or living, depending on the type of organ and the medical circumstances.
Organ transplantation is a significant and life-changing event for both the recipient and their families. It requires careful evaluation, matching, and coordination between the donor and recipient, as well as rigorous post-transplant care to ensure the success of the procedure and minimize the risk of rejection.
The Automobile Driver Examination is a medical definition that refers to the process of evaluating an individual's physical and mental fitness to operate a motor vehicle. The examination typically includes a series of tests designed to assess the person's vision, hearing, reaction time, cognitive abilities, and overall health status.
The purpose of the examination is to ensure that drivers are capable of operating their vehicles safely and reducing the risk of accidents on the road. In many jurisdictions, driver examinations are required for individuals seeking to obtain a new driver's license or renew an existing one, particularly for those in certain age groups or with medical conditions that may affect their ability to drive.
The examination is usually conducted by a licensed healthcare professional, such as a doctor or nurse practitioner, who has been trained to assess the driver's fitness to operate a motor vehicle. The results of the examination are then used to determine whether the individual is medically fit to drive and what, if any, restrictions or accommodations may be necessary to ensure their safety and the safety of others on the road.
Biometric identification is the use of automated processes to identify a person based on their unique physical or behavioral characteristics. These characteristics, known as biometrics, can include fingerprints, facial recognition, iris scans, voice patterns, and other distinctive traits that are difficult to replicate or forge. Biometric identification systems work by capturing and analyzing these features with specialized hardware and software, comparing them against a database of known individuals to find a match.
Biometric identification is becoming increasingly popular in security applications, such as access control for buildings and devices, border control, and law enforcement. It offers several advantages over traditional methods of identification, such as passwords or ID cards, which can be lost, stolen, or easily replicated. By contrast, biometric traits are unique to each individual and cannot be easily changed or duplicated.
However, there are also concerns around privacy and the potential for misuse of biometric data. It is important that appropriate safeguards are in place to protect individuals' personal information and prevent unauthorized access or use.
Medical ethics is a branch of ethics that deals with moral issues in medical care, research, and practice. It provides a framework for addressing questions related to patient autonomy, informed consent, confidentiality, distributive justice, beneficentia (doing good), and non-maleficence (not doing harm). Medical ethics also involves the application of ethical principles such as respect for persons, beneficence, non-maleficence, and justice to specific medical cases and situations. It is a crucial component of medical education and practice, helping healthcare professionals make informed decisions that promote patient well-being while respecting their rights and dignity.
Clinical ethics refers to the branch of applied ethics that deals with ethical issues in clinical settings, such as hospitals and other healthcare facilities. It involves the application of moral principles and values to decision-making in clinical practice, with the aim of promoting patient autonomy, beneficence, non-maleficence, and justice.
Clinical ethics often involves addressing complex ethical dilemmas that arise in the context of patient care, such as end-of-life decisions, informed consent, confidentiality, resource allocation, and research involving human subjects. Clinical ethicists may work as part of an institutional ethics committee or provide consultation services to healthcare providers, patients, and families facing ethical challenges.
The principles of clinical ethics are grounded in respect for patient autonomy, which includes the right to make informed decisions about their own care. Beneficence refers to the obligation to act in the best interests of the patient, while non-maleficence involves avoiding harm to the patient. Justice requires fair and equitable distribution of healthcare resources and respect for the rights and dignity of all patients.
Effective clinical ethics decision-making also involves careful consideration of contextual factors, such as cultural differences, religious beliefs, and social values, that may influence ethical judgments in particular cases. Clinical ethicists use a variety of methods to analyze ethical issues, including case consultation, ethical analysis frameworks, and moral deliberation processes that involve all stakeholders in the decision-making process.
Jean-François Bach
Włodzimierz Ptak
Medical Research Club
Michael Woodruff
Immunosuppressive drug
Thymoglobulin
Anti-lymphocyte globulin
List of MeSH codes (D12.776)
List of MeSH codes (D12.776.124)
List of MeSH codes (A12)
List of MeSH codes (D20)
Anti-thymocyte globulin
Intestine transplantation
Aplastic anemia
Rabbit antithymocyte globulin-induced serum sickness disease and human kidney graft survival
Sensitivity of amplifier T cells involved in the antibody response to type III pneumococcal polysaccharide to anti-lymphocyte...
Jean-François Bach - Wikipedia
Aplastic Anemia: Practice Essentials, Background, Etiology
Transplant - Legal, Ethical, Problems | Britannica
WHOCC - ATC/DDD Index
Aplastic Anemia: Practice Essentials, Background, Etiology
15.2.3.4
John A Goss, M.D. | BCM
PROLONGED ALLOGRAFT SURVIVAL RESULTING FROM DONOR PRETREATMENT WITH PHYTOHEMAGGLUTININ-P - McMaster Experts
Estado actual del trasplante pulmonar
DeCS
Download Cheats | VAC Undetected, HvH, Triggerbot - Spinnerstown Hotel
Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple...
Graft rejection. Medical search
Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in...
Iori Kisu - Research output - Keio University
Varun Puri - Research output - Research Profiles at Washington University School of Medicine
Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral...
Coco de Koning - Onderzoeksoutput - Prinses Máxima Centrum
A. Osama Gaber - Research output - Houston Methodist Scholars
Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: Serial...
Lymphocyte depletion in experimental hemorrhagic shock in swine<...
Influenza myocarditis treated with antithymocyte globulin<...
Volume 130 Issue 1 | Journal of Experimental Medicine | Rockefeller University Press
Aplastic Anemia Workup: Approach Considerations, Complete Blood Cell Count and Peripheral Smears, Peripheral Blood Testing
Aplastic Anemia: Practice Essentials, Background, Etiology
Ranking all cheats | No Red Trust Factor, VAC Bypass, RageBot - Cilelij 2020 España
Different Ly antigen phenotypes of in vitro induced helper and suppressor cells. - Immunology
T-T interactions in the induction of suppressor and helper T cells: analysis of membrane phenotype of precursor and amplifier...
Globulin4
- 2) Antilymphocyte Globulin (ALG) . (nanomedicine.com)
- ALG is produced by immunizing a large animal such as a horse with human lymphocytes, then purifying the gamma globulin fraction of the serum. (nanomedicine.com)
- Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. (1library.co)
- [ 1 ] Recipients were treated with intensive conventional immunosuppression , including combinations of prednisone , azathioprine , and antilymphocyte globulin. (medscape.com)
Immunosuppressants1
- the action of immunosuppressants (cyclosporin, antilymphocyte sera, monoclonal antibodies against Tlymphocytes). (wikipedia.org)
Antithymocyte1
- Antithymocyte immunoglobulin from rabbit serum is classified in L04AA04. (whocc.no)
Antibodies2
- Two subgroups of SSD(+) and SSD(-) patients that had received ATG induction treatment were then assessed for total anti-ATG, anti-Neu5Gc, and anti-Gal antibodies using ELISA assays on sera before and after transplantation. (nih.gov)
- sera from children were tested for antibodies to viral capsid antigens of epstein-barr virus. (liverpool.ac.uk)
Sickness2
- However, ATGs can induce immune complex diseases, including serum sickness disease (SSD). (nih.gov)
- Steroids are generally ineffective, though are often used to combat serum sickness caused by ATG use. (webdicine.com)
Adult1
- The evidence for the interaction of 2 subpopulations of T cells, short-lived cells sensitive to adult thymectomy (T1 cells), and long-lived recirculating cells, sensitive to the action of antilymphocyte serum (T2 cells) in the induction of helper cells is presented. (ox.ac.uk)
Animals1
- Pop, A, "Production of Laboratory Animals for the Production of Serums and Vaccines," Arch Roum Path Exp Mocrobiol, 1967, 23:423-430. (currenthealthscenario.com)
Graft1
- We analyzed data from a cohort of 889 first kidney graft recipients with ATG induction (86 with SSD [SSD(+)] and 803 without SSD [SSD(-)]) from the Données Informatisées et Validées en Transplantation data bank. (nih.gov)
Cells1
- Amplifier T cells responsible for enhancement of the antibody response to type III pneumococcal polysaccharide have been shown to be resistant to the effects of antilymphocyte serum (ALS) given at the time of immunization, a treatment that eliminates suppressor T cell activity. (johnshopkins.edu)
Kidney1
- Rapid kidney allograft failure in patients with polyoma virus nephritis with prior treatment with antilymphocyte agents. (mcw.edu)
Research1
- Lymphoprep™ is a ready-made, sterile and endotoxin tested density gradient medium recommended for the isolation of pure lymphocyte suspensions for tissue typing, anti-lymphocyte sera and immunological research. (transcriptionfactor.org)
Clinical1
- positive serum tests for infectious mononucleosis (im) unaccompanied by the clinical syndrome or blood changes characteristic of the disease were detected in 39/177 (22%) mentally subnormal patients investigated with three different commercially available im slide tests. (liverpool.ac.uk)
Treatment1
- Although antilymphocyte serum was used in the treatment of chronic lymphocytic leukemia and in T-cell and B-cell lymphomas, resulting in temporary decreases in lymphocyte counts or lymph node size, newer humoral immunotherapeutic modalities have been developed. (msdmanuals.com)
Human1
- production of interferon or interferon-like susbstances in eb3 cultures after inoculation with human serum containing australia antigen]. (liverpool.ac.uk)
Antibodies10
- the action of immunosuppressants (cyclosporin, antilymphocyte sera, monoclonal antibodies against Tlymphocytes). (wikipedia.org)
- Serum that contains antibodies. (umassmed.edu)
- Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS . (bvsalud.org)
- Antilymphocyte antibodies include polyclonal preparations, such as equine antithymocyte globulin (ATGAM) and rabbit antithymocyte globulin (Thymoglobulin), and the monoclonal antibody preparations muromonab-CD3 (OKT3) and anti-CD52 (Alemtuzumab). (pharmapedia.pk)
- Antilymphocyte antibodies act by lymphodepletion, as well as by interactions with cellular receptors. (pharmapedia.pk)
- Autoantibodies (autoAbs) to cell-surface molecules, including antilymphocyte antibodies, are often detected in the sera of patients with systemic autoimmune diseases such as systemic lupus erythematosus (SLE). (biomedcentral.com)
- METHODS IgG anti-P antibodies in the sera of 267 patients with CTDs and 31 healthy subjects were analysed by immunoblotting performed on cytoplasmic extract of Raji cells. (bmj.com)
- A close association of IgG antibodies with P proteins and with cardiolipin was seen in lupus sera (p=0.0009, odds ratio 18.33). (bmj.com)
- Anti-P antibodies from 9 of 12 anti-P lupus serum samples could be affinity purified and none of the affinity purified fractions cross reacted with ELISA plate coated cardiolipin. (bmj.com)
- Anti-P antibodies are strongly clustered with IgG anticardiolipin antibodies in lupus sera, even if they are independently elicited. (bmj.com)
Globulin6
- Twenty-two patients with aplastic anemia were treated with antilymphocyte serum or antithymocyte globulin at Vanderbilt University and affiliated hospitals from 1980 to 1986. (nih.gov)
- Twenty patients received antilymphocyte serum initially while two patients received antithymocyte globulin. (nih.gov)
- Fifteen patients received fluoxymesterone 10 mg by mouth three times a day with antilymphocyte serum, and all received prednisone during the course of antilymphocyte serum or antithymocyte globulin. (nih.gov)
- Eight patients with no initial response and a patient who experienced a relapse after a complete response were re-treated with either antithymocyte globulin (six) or antilymphocyte serum (three), with four of nine patients (44 percent) having a response (three complete responses, one partial response). (nih.gov)
- ALG (Thymoglobulin) and antithymocyte globulin (ATG) are less commonly used antilymphocyte antibody preparations. (pharmapedia.pk)
- Antilymphocyte globulin (ALG) and antithymocyte globulin (ATG) are produced by extracting immunoglobulins from animals (usually horse or rabbit) that have been immunized with human lymphocytes or thymocytes, respectively. (pharmapedia.pk)
Lymphocyte5
- Opsonizing activity of anti-human lymphocyte serum. (jax.org)
- 8. Combined host-conditioning with CTLA4-Ig, tacrolimus, anti-lymphocyte serum, and low-dose radiation leads to stable mixed hematopoietic chimerism. (nih.gov)
- 11. A partial conditioning strategy for achieving mixed chimerism in the rat: tacrolimus and anti-lymphocyte serum substantially reduce the minimum radiation dose for engraftment. (nih.gov)
- Although antilymphocyte serum was used in the treatment of chronic lymphocytic leukemia and in T-cell and B-cell lymphomas, resulting in temporary decreases in lymphocyte counts or lymph node size, newer humoral immunotherapeutic modalities have been developed. (msdmanuals.com)
- LymphoprepTM can be used for the preparation of pure lymphocyte suspensions for tissue typing, antilymphocyte sera, and immunological research. (microsensbp.com)
Immunoglobulin2
ANTIGENS1
- A characteristic feature of patients with connective tissue diseases (CTDs) is detection of high levels of autoantibodies to intracellular "self" antigens in the serum. (bmj.com)
Antibody1
- Delayed cases of antibody mediated rejection present as an acute rise in the serum creatinine with or without graft tenderness. (upmc.com)
Thymoglobulin1
- Of these antilymphocyte agents, Thymoglobulin is currently predominant, and the use of the others is either rare or of historic interest. (pharmapedia.pk)
Immunosuppressive2
- Assay for the immunosuppressive capacity of antilymphocyte serum. (jax.org)
- Most centers include induction therapy with an antilymphocyte agent in their immunosuppressive regimens. (medscape.com)
PMID1
- PMID- 5157696 TI - [IgA in the gastric content and in the serum of eutrophic and malnourished infants]. (nih.gov)
Immunoglobulins1
- Commonly observed side effects include allergic reactions, serum sickness, fever, and thrombocytopenia, as with OKT3 and other systemically infused immunoglobulins. (pharmapedia.pk)
Immune3
- Immune Sera" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (umassmed.edu)
- This graph shows the total number of publications written about "Immune Sera" by people in this website by year, and whether "Immune Sera" was a major or minor topic of these publications. (umassmed.edu)
- Below are the most recent publications written about "Immune Sera" by people in Profiles. (umassmed.edu)
Chronic lymphocy1
- Clinico-prognostic implications of increased levels of soluble CD54 in the serum of B-cell chronic lymphocytic leukemia patients. (haematologica.org)
Rejection1
- Careful attention to fasting blood glucose levels and upward trends in serum amylase, lipase, and glucose levels may be useful in the clinical detection of rejection, but are usually not apparent until late in the rejection process. (medscape.com)
Induction1
- The use of antilymphocyte induction regimens has declined precipitously with time. (pharmapedia.pk)
Disease1
- Using six recombinant proteins (F2-F7) for LRP2 and one for CD69, we detected autoAbs to LRP2 in sera of patients with rheumatoid arthritis (RA), systemic lupus erythematosus, Behçet's disease, systemic sclerosis, and osteoarthritis and then mapped autoepitopes by Western blotting. (biomedcentral.com)
Activation1
- Granoff DM, Welsch JA, Ram S. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. (umassmed.edu)
Implications1
- Enhanced factor H binding to sialylated Gonococci is restricted to the sialylated lacto-N-neotetraose lipooligosaccharide species: implications for serum resistance and evidence for a bifunctional lipooligosaccharide sialyltransferase in Gonococci. (umassmed.edu)
Patients1
- In addition, iron chelation may be required in chronically transfused patients who develop elevated serum ferritin levels above 1000 µg/L. (medscape.com)
Effective2
Samples1
- Multiple epitopes on LRP2 were recognized by most of the anti-LRP2 + serum samples. (biomedcentral.com)
Major1
- A major limitation of all polyclonal antilymphocyte preparations is batch-to-batch heterogeneity, which results in unpredictable side effects and more importantly, variable efficacy. (pharmapedia.pk)